Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center, reshared a post by Bristol Myers Squibb on X, adding:
“Great day for lung cancer care!
Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer!”
Quoting Bristol Myers Squibb‘s post:
“MEDIA:
Announcing the final analysis of OS from the CheckMate -816 trial evaluating our immunotherapy used in combination with chemotherapy regimen as neoadjuvant treatment of resectable non-small cell lung cancer.”
